Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc (symbol: MDT) is the issuer of record for a Form 425 filing submitted to the SEC.
Medtronic plc (symbol: MDT) is the issuer of record for a Form 425 filing submitted to the SEC.
Medtronic plc (MDT) states that it intends to split off its remaining ownership in MiniMed through an exchange offer, as the next step in separating MiniMed into a standalone, fully independent company. This follows MiniMed’s initial public offering on March 6 and is described as another milestone in that separation process.
The communication emphasizes that the exchange offer will be made solely by the prospectus included in MiniMed’s registration statement on Form S-4 and related documents, and that none of Medtronic, MiniMed, their directors or officers, or the dealer managers are recommending whether holders should participate. It also includes extensive forward-looking statements language outlining risks and uncertainties and urges investors and security holders to read the prospectus, Schedule TO, and other SEC filings before making any investment decision.
Medtronic plc (MDT) announced its intention to complete the separation of MiniMed by offering shareholders an exchange offer, allowing them to exchange all, some, or none of their Medtronic shares for MiniMed (MMED) shares at a discount. As shareholders elect to exchange, Medtronic’s ownership stake in MiniMed will decrease, and once the exchange offer and related transactions are completed, Medtronic will no longer hold an equity stake in MiniMed and MiniMed will operate as an independent company. Participation is voluntary for shareholders, including employees, with eligibility and mechanics differing between brokerage-held shares and shares held through the Employee Stock Purchase Plan.
Medtronic plc (MDT) outlines a split-off Exchange Offer to divest most or all of its stake in diabetes business MiniMed Group, Inc. by offering up to 225,361,295 newly issued MiniMed shares, representing 80.1% of MiniMed, to Medtronic shareholders in exchange for Medtronic ordinary shares. If the offer is oversubscribed, Medtronic currently intends to exchange an additional 27,452,053 MiniMed shares (its remaining interest, taking its ownership from 89.9% to zero) for additional Medtronic shares, reducing Medtronic’s share count without using cash.
The transaction is intended to be tax-free for U.S. federal income tax purposes under Section 355, and the exchange ratio is designed so $100 of Medtronic shares would receive about $107.53 of MiniMed stock, subject to an upper limit of 4.5939 MiniMed shares per Medtronic share and VWAP-based pricing. After the exchange, MiniMed will be an independent diabetes-focused company and does not expect to pay dividends for the foreseeable future, while Medtronic shares acquired will be redeemed and cancelled.
Medtronic plc (symbol: MDT) is the issuer of record for a Form 425 filing submitted to the SEC.
Medtronic plc (symbol: MDT) is the issuer of record for a Form SC TO-I filing submitted to the SEC.
Medtronic plc (MDT) has launched a voluntary exchange offer to complete the separation of its former Diabetes business, MiniMed Group, Inc., by splitting off at least 80.1% of MiniMed shares it currently owns. Medtronic now holds 252,813,348 MiniMed shares, about 90% of MiniMed’s outstanding common stock, and is offering to exchange up to 225,361,295 of those shares for Medtronic ordinary shares, with the potential to exchange its entire remaining interest if the offer is oversubscribed. Medtronic shareholders who participate can exchange their MDT shares for MiniMed stock at a 7% discount, targeting approximately $107.53 of MiniMed stock for every $100 of MDT tendered, subject to an upper limit of 4.5939 MiniMed shares per Medtronic share. The exchange ratio will be set using the volume-weighted average prices from October 5–7, 2026 and announced before the expected October 9, 2026 expiration, and the transaction is expected to be generally tax-free for U.S. federal income tax purposes, subject to conditions including a minimum of 112,680,647 MiniMed shares being exchanged.
Medtronic plc (symbol: MDT) is the issuer of record for a Form 425 filing submitted to the SEC.